Recently published statistics reveal that Saudi Arabia’s total spending on health constituted eight percent of the GDP over the past 10 years, amounting to 3.37 billion Saudi riyals ($898.6 million) per annum, reported Al-Bayan.
The same sources added that the private sector receives 70 percent of the imported pharmaceuticals while the rest is directed to governmental agencies. The major foreign pharmaceutical companies in Saudi Arabia are Smithrline, Hoechst, Lilly, Novartis, fizer and Beecham. — (menareport.com)
© 2001 Mena Report (www.menareport.com)
